VVUS - Risky But Moving Up And Reclaiming LossesVIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.
SHORT INTEREST
541.95K 07/31/19
P/E Current
-1.14
P/E Ratio (with extraordinary items)
-1.53
Average Recommendation: HOLD
Average Target Price: 10.00
VVUS
VVUS CHANNEL BROKEN: ONE MORE WAVE UP?VVUS has broken the descending channel with a strong impulse. Are there possibilities for one more wave up?
VVUS hits a bottom. Breaking out of falling wedge formation- Qysmia looks to be gaining from new online marketing efforts
- Endo will start promoting Vivus' ED drug
- 36% short interest!
- Institutional investors adding at these levels
- Recently hit a 10-year-low, but things have never looked brighter for VVUS
PT: $10
Timeframe: 18 - 24 months (possibly sooner, depending on how ED drug sales are)
Disclosure: Long $2 Jan 2017 calls @1.10/contract
